RDEB-iPSC-d3A
RNRMUi003-A
General
Cell Line |
|
| hPSCreg name | RNRMUi003-A |
| Cite as: | RNRMUi003-A (RRID:CVCL_D0MS) |
| Alternative name(s) |
RDEB-iPSC-d3A
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
RNRMUi005-A (EB-iPSC-d4, RDEB-iPSC-d4) Donor diseases: Epidermolysis Bullosa Simplex recessive dystrophic epidermolysis bullosa UNIZARi001-A (FiPSTK2-2) Donor's gene variants: TK2, TK2 Donor diseases: Mitochondrial DNA depletion syndrome, myopathic form HDZi003-A (hiPSC NP0038) Donor's gene variants: TMEM43 Donor diseases: arrhythmogenic right ventricular dysplasia 5 HIHDNDi001-A (A30P-3, SNCA3, Tue_020_A) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 HIHDNDi001-B (A30P-4, SNCA4, Tue_020_B) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 |
| Last update | 29th June 2023 |
| User feedback | |
Provider |
|
| Generator | Pirogov Russian National Research Medical University (RNRMU) |
| Owner | Pirogov Russian National Research Medical University (RNRMU) |
| Derivation country | Russia |
External Databases |
|
| BioSamples | SAMEA113966806 |
| Cellosaurus | CVCL_D0MS |
| Wikidata | Q123033363 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 25-29 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
Karyotyping method:
G-Banding
|
External Databases (Donor) |
|
| BioSamples | SAMEA113966808 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Local ethic commission of Pirogov RSMU |
| Approval number | №192 from 01.27.2019 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type | |
| Age of donor (at collection) | 25-29 |
| Collected in | 2020 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Phase contrast microscopy - large nucleus and densely packed cells grow in colonies. Immunofluorescence - expression of SOX2, OCT4, SSEA-4, TRA-1-60 and TRA-1-81. RT-PCR - expression of LIN28, OCT4, NANOG, REX12, TDGF and SOX2. |
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Yes |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ Plus
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SOX2 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
Morphology pictures
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
normal, xy
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.